CEO Update: August 2020

CEO Update: August 2020

InSitu Biologics has made considerable progress executing our business plan over the past several months, even in the midst of ongoing COVID-19 challenges.  We recently raised over $2 million in a convertible note financing round, received a pre-investigational new...
CEO Update: April 2020

CEO Update: April 2020

InSitu Biologics has continued to make great strides over the past few months. We have successfully submitted our Pre-IND application to the FDA, as well as applied for a National Institute of Health federal grant to support our development costs. During this time of...